Insmed Incorporated (INSM) Stock Forecast
INSM analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.71 / 5 from 24 analysts
- Price target
- $197.00 average of analyst targets
- Upside to target
- +104.6% from the latest close
- Next earnings
- October 29, 2026 EPS estimate $-0.35
- 52-week range
- $91.88 – $211.41
INSM analyst ratings
24 analystsNumber of analysts at each rating.
INSM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
INSM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.38 | −$0.90 | −$0.09 | −$1.75 | +78.4% | 18 |
| Current fiscal year (2026) | −$1.59 | −$2.65 | −$0.80 | −$6.42 | +75.2% | 18 |
| Next fiscal year (2027) | $0.80 | −$0.91 | $2.91 | −$1.59 | +150.1% | 17 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
INSM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $497.6M | $457.0M | $514.8M | +249.6% | 21 |
| Current fiscal year (2026) | $1.80B | $1.66B | $1.87B | +196.8% | 22 |
| Next fiscal year (2027) | $2.91B | $2.59B | $3.44B | +61.7% | 20 |
INSM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
INSM revenue: reported and forecast
INSM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.61 | −$0.36 | −$0.36 | −$0.37 | −$0.38 | −38.0% | 0 up · 3 down |
| Current fiscal year (2026) | −$2.59 | −$1.55 | −$1.54 | −$1.57 | −$1.59 | −38.6% | 1 up · 4 down |
| Next fiscal year (2027) | $0.13 | $0.72 | $0.77 | $0.79 | $0.80 | +499.6% | 3 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
INSM earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; INSM beat in 4 of 12.
What analysts expect from INSM
24 analysts cover Insmed; their consensus rating is strong buy (4.71 on a 1–5 scale, where 5 is a strong buy). The average price target is $197.00, 104.6% above the latest close of $96.27. Analysts expect earnings of −$1.59 per share for 2026, +75.2% from a year earlier. For 2027 the average estimate is $0.80 per share on revenue of $2.9 billion. Insmed beat the EPS estimate in 4 of the last 12 quarters.
Related: INSM income statement, INSM key metrics, INSM chart. See the INSM stock overview for the latest quote and news.
INSM forecast FAQ
What is Insmed's price target?
The average analyst price target for Insmed is $197.00, 104.6% above the latest close of $96.27.
Is Insmed a buy, hold or sell?
Of 24 analysts covering Insmed, 18 rate it a strong buy, 5 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Insmed's EPS forecast?
Analysts forecast −$1.59 per share for 2026 (range −$2.65 to −$0.80); for 2027 the estimate is $0.80.
What is Insmed's revenue forecast?
The average revenue estimate for 2026 is $1.8 billion, growth of 196.8%; for 2027 it is $2.9 billion.
When does Insmed report earnings?
Insmed is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 before the market opens; the EPS estimate is $-0.35.
Does Insmed usually beat earnings estimates?
Insmed reported EPS at or above the analyst estimate in 4 of the last 12 quarters.